Wall Street is buzzing about Gilead’s new rheumatoid arthritis drug. Here’s why
March 29, 2019 at 13:03 PM EDT
Shares of Belgium-based biotech Galapagos NV soared 23% on Friday after the company, together with pharmaceutical giant Gilead Sciences Inc., announced Thursday evening that two Phase 3 trials of their investigational rheumatoid arthritis drug had achieved their primary endpoints.